Cancer Patients' decisions shaped by drug benefit uncertainties, study finds

NCT ID NCT07694310

Not yet recruiting Knowledge-focused Sponsor: London School of Economics and Political Science Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study investigates how providing information about uncertainties in new cancer drugs' benefits influences patients' hypothetical treatment decisions and perceptions. Researchers will present current or former cancer patients with a scenario about a new drug called Zenova, which shrinks tumors but has unknown effects on survival or quality of life. Participants will then indicate how likely they would be to take the drug and rate its effectiveness. The goal is to understand whether transparency about drug uncertainties changes patient preferences.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If it works, this could help doctors and regulators communicate drug uncertainties more clearly, leading to better-informed patient decisions.
What could go wrong: This is a hypothetical survey, not a real treatment trial. Results may not reflect actual patient choices in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.